Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Клиническая эффективность и фармакокинетика глифлозинов с точки зрения индивидуальных генетических особенностей
Головина Е.Л., Ваизова О.Е., Мелешко М.В., Самойлова Ю.Г., Подчиненова Д.В., Борозинец А.А., Матвеева М.В., Кудлай Д.А. Клиническая эффективность и фармакокинетика глифлозинов с точки зрения индивидуальных генетических особенностей. Терапевтический архив. 2023;95(8):706–709.
DOI: 10.26442/00403660.2023.08.202326
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
DOI: 10.26442/00403660.2023.08.202326
© ООО «КОНСИЛИУМ МЕДИКУМ», 2023 г.
________________________________________________
Golovina EL, Vaizova OE, Meleshko MV, Samoilova IuG, Podchinenova DV, Borozinets AA, Matveeva MV, Kudlay DA. Clinical effectiveness and pharmacokinetics of gliflozin from the point of view of individual genetic characteristics: A review. Terapevticheskii Arkhiv (Ter. Arkh.). 2023;95(8):706–709.DOI: 10.26442/00403660.2023.08.202326
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Представлен обзор публикаций, посвященных анализу генетических полиморфизмов и особенностей функционирования генов, влияющих на фармакокинетику и фармакодинамику ингибиторов натрий-глюкозного котранспортера 2-го типа (SGLT2i). Задачей являлось выявление информации о генах, полиморфизм которых может оказывать влияние на SGLT2i. Обзор проводили в соответствии с рекомендациями PRISMA 2020. Публикации проанализировали в базах данных PubMed (включая Medline), Web of Science, а также в российской научной электронной библиотеке eLIBRARY.RU за период 1993–2022 гг. Описаны полиморфизмы в строении генов SLC5A2, UGT1A9, ABCB1, PNPLA3, которые могут оказывать влияние на терапию сахарного диабета 2-го типа, осложненного такими заболеваниями, как хроническая сердечная недостаточность, хроническая болезнь почек или неалкогольная жировая болезнь печени. Найденная информация о генетических особенностях развития эффектов SGLT2i ограничена описанием различий их фармакокинетики. Актуальность доступных фармакогенетических исследований в значительной степени сдерживается небольшими размерами выборок.
Ключевые слова: гены, полиморфизм, сахарный диабет 2-го типа, хроническая сердечная недостаточность, хроническая болезнь почек, неалкогольная жировая болезнь печени, ингибиторы натрий-глюкозного котранспортера 2-го типа, дапаглифлозин, канаглифлозин, эмпаглифлозин
Ключевые слова: гены, полиморфизм, сахарный диабет 2-го типа, хроническая сердечная недостаточность, хроническая болезнь почек, неалкогольная жировая болезнь печени, ингибиторы натрий-глюкозного котранспортера 2-го типа, дапаглифлозин, канаглифлозин, эмпаглифлозин
________________________________________________
A review of publications devoted to the analysis of genetic polymorphisms and features of the functioning of genes that affect the pharmacokinetics and pharmacodynamics of sodium-glucose cotransporter-2 inhibitors (SGLT2i) is presented. Objective of the study was to reveal information about genes whose polymorphism may affect the effectiveness of SGLT2i. The review was carried out in accordance with the PRISMA 2020 recommendations, the search for publications was carried out in the PubMed databases (including Medline), Web of Science, as well as Russian scientific electronic libraries eLIBRARY.RU from 1993 to 2022. Polymorphisms in the structure of several genes (SLC5A2, UGT1A9, ABCB1, PNPLA3) have been described that may affect the treatment of type 2 diabetes mellitus complicated by diseases such as chronic heart failure, chronic kidney disease, or non-alcoholic fatty liver disease. The information found on the genetic features of the development of the effects of SGLT2i is limited to a description of the differences in their pharmacokinetics. The relevance of currently available pharmacogenetic studies is largely constrained by small sample sizes.
Keywords: genes, polymorphism, diabetes mellitus type 2, chronic heart failure, chronic kidney disease, non-alcoholic fatty liver disease, sodium glucose cotransporter 2 inhibitors, dapagliflozin, canagliflozin, empagliflozin
Полный текст
Список литературы
1. Imamovic Kadric S, Kulo Cesic A, Dujic T. Pharmacogenetics of new classes of antidiabetic drugs. Bosn J Basic Med Sci. 2021;21(6):659-71. DOI:10.17305/bjbms.2021.5646
2. Российская ассоциация эндокринологов. Клинические рекомендации по лечению сахарного диабета 2 типа у взрослых. Режим доступа: https://cr.minzdrav.gov.ru/schema/290_2. Ссылка активна на 30.04.2023 [Rossiiskaia assotsiatsiia endokrinologov. Klinicheskie rekomendatsii po lecheniiu sakharnogo diabeta 2 tipa u vzroslykh. Available at: https://cr.minzdrav.gov.ru/schema/290_2. Accessed: 30.04.2023 (in Russian)].
3. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. DOI:10.1152/physrev.00055.2009
4. Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Попов С.И. Ингибиторы SGLT2 и почки: механизмы и основные эффекты у больных сахарным диабетом 2 типа. Сахарный диабет. 2020;23(5):475-91 [Salukhov VV, Khalimov YuS, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus. 2020;23(5):475-91 (in Russian)]. DOI:10.14341/DM12123
5. Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287-302. DOI:10.1080/17425255.2018.1551877
6. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-25. DOI:10.1007/s00125-018-4663-6
7. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. DOI:10.1080/14740338.2019.1602116
8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. DOI:10.1056/NEJMoa2024816
9. Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics. 1993;17(3):787-9. DOI:10.1006/geno.1993.1411
10. Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 2017;27(4):135-42. DOI:10.1097/FPC.0000000000000268
11. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119-26. DOI:10.2217/pgs.11.69
12. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-7. DOI:10.1038/nm.3828
13. Ordelheide AM, Böhm A, Kempe-Teufel D, et al. Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS One. 2017;12(5):e0177148. DOI:10.1371/journal.pone.0177148
14. Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001;11(4):357-68. DOI:10.1097/00008571-200106000-00011
15. Naagaard MD, Chang R, Någård M, et al. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. Br J Clin Pharmacol. 2022;88(4):1942-6. DOI:10.1111/bcp.15117
16. Hoeben E, De Winter W, Neyens M, et al. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet. 2016;55(2):209-23. DOI:10.1007/s40262-015-0307-x
17. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061-72. DOI:10.1002/jcph.506
18. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61. DOI:10.1097/FPC.0b013e3283385a1c
19. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285‑307. DOI:10.1146/annurev.pharmtox.43.100901.140233
20. Hwang JG, Jeong SI, Kim YK, et al. Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol. 2022;30(4):212-25. DOI:10.12793/tcp.2022.30.e23
21. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-14. DOI:10.1124/dmd.109.029165
22. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147-54. DOI:10.1097/00008571-200403000-00002
23. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018;293(18):6958-68. DOI:10.1074/jbc.RA118.002333
24. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-53. DOI:10.1136/gutjnl-2017-313884
25. Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-80. DOI:10.1111/hepr.12856
26. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923‑34. DOI:10.1007/s00125-018-4675-2
27. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461‑5. DOI:10.1038/ng.257
2. Российская ассоциация эндокринологов. Клинические рекомендации по лечению сахарного диабета 2 типа у взрослых. Режим доступа: https://cr.minzdrav.gov.ru/schema/290_2. Ссылка активна на 30.04.2023 [Rossiiskaia assotsiatsiia endokrinologov. Klinicheskie rekomendatsii po lecheniiu sakharnogo diabeta 2 tipa u vzroslykh. Available at: https://cr.minzdrav.gov.ru/schema/290_2. Accessed: 30.04.2023 (in Russian)].
3. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. DOI:10.1152/physrev.00055.2009
4. Салухов В.В., Халимов Ю.Ш., Шустов С.Б., Попов С.И. Ингибиторы SGLT2 и почки: механизмы и основные эффекты у больных сахарным диабетом 2 типа. Сахарный диабет. 2020;23(5):475-91 [Salukhov VV, Khalimov YuS, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus. 2020;23(5):475-91 (in Russian)]. DOI:10.14341/DM12123
5. Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287-302. DOI:10.1080/17425255.2018.1551877
6. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-25. DOI:10.1007/s00125-018-4663-6
7. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. DOI:10.1080/14740338.2019.1602116
8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. DOI:10.1056/NEJMoa2024816
9. Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics. 1993;17(3):787-9. DOI:10.1006/geno.1993.1411
10. Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 2017;27(4):135-42. DOI:10.1097/FPC.0000000000000268
11. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119-26. DOI:10.2217/pgs.11.69
12. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-7. DOI:10.1038/nm.3828
13. Ordelheide AM, Böhm A, Kempe-Teufel D, et al. Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS One. 2017;12(5):e0177148. DOI:10.1371/journal.pone.0177148
14. Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001;11(4):357-68. DOI:10.1097/00008571-200106000-00011
15. Naagaard MD, Chang R, Någård M, et al. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. Br J Clin Pharmacol. 2022;88(4):1942-6. DOI:10.1111/bcp.15117
16. Hoeben E, De Winter W, Neyens M, et al. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet. 2016;55(2):209-23. DOI:10.1007/s40262-015-0307-x
17. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061-72. DOI:10.1002/jcph.506
18. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61. DOI:10.1097/FPC.0b013e3283385a1c
19. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285‑307. DOI:10.1146/annurev.pharmtox.43.100901.140233
20. Hwang JG, Jeong SI, Kim YK, et al. Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol. 2022;30(4):212-25. DOI:10.12793/tcp.2022.30.e23
21. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-14. DOI:10.1124/dmd.109.029165
22. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147-54. DOI:10.1097/00008571-200403000-00002
23. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018;293(18):6958-68. DOI:10.1074/jbc.RA118.002333
24. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-53. DOI:10.1136/gutjnl-2017-313884
25. Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-80. DOI:10.1111/hepr.12856
26. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923‑34. DOI:10.1007/s00125-018-4675-2
27. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461‑5. DOI:10.1038/ng.257
________________________________________________
1. Imamovic Kadric S, Kulo Cesic A, Dujic T. Pharmacogenetics of new classes of antidiabetic drugs. Bosn J Basic Med Sci. 2021;21(6):659-71. DOI:10.17305/bjbms.2021.5646
2. Rossiiskaia assotsiatsiia endokrinologov. Klinicheskie rekomendatsii po lecheniiu sakharnogo diabeta 2 tipa u vzroslykh. Available at: https://cr.minzdrav.gov.ru/schema/290_2. Accessed: 30.04.2023 (in Russian).
3. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. DOI:10.1152/physrev.00055.2009
4. Salukhov VV, Khalimov YuS, Shustov SB, Popov SI. SGLT2 inhibitors and kidneys: mechanisms and main effects in diabetes mellitus patients. Diabetes Mellitus. 2020;23(5):475-91 (in Russian). DOI:10.14341/DM12123
5. Garcia-Ropero A, Badimon JJ, Santos-Gallego CG. The pharmacokinetics and pharmacodynamics of SGLT2 inhibitors for type 2 diabetes mellitus: the latest developments. Expert Opin Drug Metab Toxicol. 2018;14(12):1287-302. DOI:10.1080/17425255.2018.1551877
6. Lupsa BC, Inzucchi SE. Use of SGLT2 inhibitors in type 2 diabetes: weighing the risks and benefits. Diabetologia. 2018;61(10):2118-25. DOI:10.1007/s00125-018-4663-6
7. Scheen AJ. An update on the safety of SGLT2 inhibitors. Expert Opin Drug Saf. 2019;18(4):295-311. DOI:10.1080/14740338.2019.1602116
8. Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-46. DOI:10.1056/NEJMoa2024816
9. Wells RG, Mohandas TK, Hediger MA. Localization of the Na+/glucose cotransporter gene SGLT2 to human chromosome 16 close to the centromere. Genomics. 1993;17(3):787-9. DOI:10.1006/geno.1993.1411
10. Zimdahl H, Haupt A, Brendel M, et al. Influence of common polymorphisms in the SLC5A2 gene on metabolic traits in subjects at increased risk of diabetes and on response to empagliflozin treatment in patients with diabetes. Pharmacogenet Genomics. 2017;27(4):135-42. DOI:10.1097/FPC.0000000000000268
11. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011;12(8):1119-26. DOI:10.2217/pgs.11.69
12. Bonner C, Kerr-Conte J, Gmyr V, et al. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat Med. 2015;21(5):512-7. DOI:10.1038/nm.3828
13. Ordelheide AM, Böhm A, Kempe-Teufel D, et al. Common variation in the sodium/glucose cotransporter 2 gene SLC5A2 does neither affect fasting nor glucose-suppressed plasma glucagon concentrations. PLoS One. 2017;12(5):e0177148. DOI:10.1371/journal.pone.0177148
14. Gong QH, Cho JW, Huang T, et al. Thirteen UDPglucuronosyltransferase genes are encoded at the human UGT1 gene complex locus. Pharmacogenetics. 2001;11(4):357-68. DOI:10.1097/00008571-200106000-00011
15. Naagaard MD, Chang R, Någård M, et al. Common UGT1A9 polymorphisms do not have a clinically meaningful impact on the apparent oral clearance of dapagliflozin in type 2 diabetes mellitus. Br J Clin Pharmacol. 2022;88(4):1942-6. DOI:10.1111/bcp.15117
16. Hoeben E, De Winter W, Neyens M, et al. Population Pharmacokinetic Modeling of Canagliflozin in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus. Clin Pharmacokinet. 2016;55(2):209-23. DOI:10.1007/s40262-015-0307-x
17. Francke S, Mamidi RN, Solanki B, et al. In vitro metabolism of canagliflozin in human liver, kidney, intestine microsomes, and recombinant uridine diphosphate glucuronosyltransferases (UGT) and the effect of genetic variability of UGT enzymes on the pharmacokinetics of canagliflozin in humans. J Clin Pharmacol. 2015;55(9):1061-72. DOI:10.1002/jcph.506
18. Hodges LM, Markova SM, Chinn LW, et al. Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenet Genomics. 2011;21(3):152-61. DOI:10.1097/FPC.0b013e3283385a1c
19. Schwab M, Eichelbaum M, Fromm MF. Genetic polymorphisms of the human MDR1 drug transporter. Annu Rev Pharmacol Toxicol. 2003;43:285‑307. DOI:10.1146/annurev.pharmtox.43.100901.140233
20. Hwang JG, Jeong SI, Kim YK, et al. Common ABCB1 SNP, C3435T could affect systemic exposure of dapagliflozin in healthy subject. Transl Clin Pharmacol. 2022;30(4):212-25. DOI:10.12793/tcp.2022.30.e23
21. Obermeier M, Yao M, Khanna A, et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans. Drug Metab Dispos. 2010;38(3):405-14. DOI:10.1124/dmd.109.029165
22. Haufroid V, Mourad M, Van Kerckhove V, et al. The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenetics. 2004;14(3):147-54. DOI:10.1097/00008571-200403000-00002
23. Mitsche MA, Hobbs HH, Cohen JC. Patatin-like phospholipase domain-containing protein 3 promotes transfer of essential fatty acids from triglycerides to phospholipids in hepatic lipid droplets. J Biol Chem. 2018;293(18):6958-68. DOI:10.1074/jbc.RA118.002333
24. Adams LA, Anstee QM, Tilg H, Targher G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut. 2017;66(6):1138-53. DOI:10.1136/gutjnl-2017-313884
25. Sumida Y, Seko Y, Yoneda M; Japan Study Group of NAFLD (JSG-NAFLD). Novel antidiabetic medications for non-alcoholic fatty liver disease with type 2 diabetes mellitus. Hepatol Res. 2017;47(4):266-80. DOI:10.1111/hepr.12856
26. Eriksson JW, Lundkvist P, Jansson PA, et al. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923‑34. DOI:10.1007/s00125-018-4675-2
27. Romeo S, Kozlitina J, Xing C, et al. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease. Nat Genet. 2008;40(12):1461‑5. DOI:10.1038/ng.257
Авторы
Е.Л. Головина*1, О.Е. Ваизова1, М.В. Мелешко1, Ю.Г. Самойлова1, Д.В. Подчиненова1, А.А. Борозинец2, М.В. Матвеева1, Д.А. Кудлай2,3
1ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России, Томск, Россия;
2ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3ФГБУ «Государственный научный центр “Институт иммунологии”» ФМБА России, Москва, Россия
*el@ssmu.ru
1ФГБОУ ВО «Сибирский государственный медицинский университет» Минздрава России, Томск, Россия;
2ФГАОУ ВО «Первый Московский государственный медицинский университет им. И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия;
3ФГБУ «Государственный научный центр “Институт иммунологии”» ФМБА России, Москва, Россия
*el@ssmu.ru
________________________________________________
Evgenya L. Golovina*1, Olga E. Vaizova1, Marina V. Meleshko1, Iuliia G. Samoilova1, Daria V. Podchinenova1, Anastasiia A. Borozinets2, Mariia V. Matveeva1, Dmitry A. Kudlay2,3
1Siberian State Medical University, Tomsk, Russia;
2Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia;
3National Research Center – Institute of Immunology, Moscow, Russia
*el@ssmu.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.